Lupin, Inc.

Nilesh Raghunath Khedkar

Venkata Poornapragnacharyulu Palle

Rajender Kumar Kamboj

Neelima Sinha

Nageswara Rao Irlapati

Zubair Abdul Wajid Shaikh

Milind Dattatraya Sindkhedkar

Manojkumar Ramprasad Shukla

Prathap Sreedharan Nair

Gokul Keruji Deshmukh

Samiron Phukan

Sachin Sethi

Kiran Chandrashekhar Kulkarni

Pradeep Rangrao Patil

Rahul Shripad Nandurdikar

Ravindra Babanrao Jape

Dagadu Dube

Vikas Sitaram Tambe

Pradip Balu Wagh

Sudhakar Maruti Balgude

Ganesh Kakade

Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, Formula (I) wherein, ring A, Rto R, X, Y, m, and n are as defined herein, for use as SOS1 inhibitors in the treatment of proliferative, infectious and RASopathy diseases or disorders. Also disclosed are methods of synthesizing the compound of formula I, pharmaceutical compositions containing the compound of formula I, method of treatment of proliferative, infectious and RASopathy diseases or disorder, for example, a cancer, by administering the said compound and combinations of the compound of formula I with other active ingredients.

Substituted tricyclic compounds

The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium release-activated calcium (CRAC) channel. The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium release-activated calcium (CRAC) channel modulators. wherein, ring D is Formula (a) or Formula (b): A and B, which may be same or different, are independently CRor N; Y is CRor N; L is selected from &#x2014;NRC(O)&#x2014;, &#x2014;C(O)NR&#x2014; and &#x2014;NRCRR&#x2014;; Rand Rare independently hydrogen, halogen or substituted or unsubstituted alkyl; ring E is selected from the Formula (i) to (vii).

Substituted heterocyclic compounds as CRAC modulators

The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release-activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel. 

Substituted pyrazole compounds as CRAC modulators

Growing community of inventors

Maharashtra, India

Nilesh Raghunath Khedkar